复方苦参注射液与顺铂腹腔灌注化疗联合治疗胃癌恶性腹水

目的:探讨复方苦参注射液与顺铂腹腔灌注化疗在胃癌恶性腹水患者中的联合应用价值。方法:选取2012年1月—2013年12月期间南阳市中心医院收治的胃癌恶性腹水患者96例,采用随机数字表法将其分为研究组和对照组,各48例。研究组胃癌恶性腹水患者采用复方苦参注射液联合顺铂腹腔灌注化疗,对照组胃癌恶性腹水患者则采用单纯的顺铂腹腔灌注化疗,并分别对两组患者的临床治疗情况进行比较和分析。结果:与对照组比较,研究组胃癌恶性腹水患者的部分缓解率、总有效率均明显提高(P0.05),生活质量改善率明显提升(P0.05),降低率显著减少(P0.01),NK细胞,CD3~+细胞均明显提升(P0.05),CD4~+细胞,CD4~+/CD8~+均显著提高(P0.01),CD8+细胞显著降低(P0.01),不良反应总发生率显著降低(P0.01)。结论:复方苦参注射液联合顺铂腹腔灌注治疗对于提高胃癌恶性腹水患者临床疗效,改善生活质量,增强免疫能力,减少不良反应等方面均具有极其重要的现实意义。

Combination of Compound Kushen Injection and Cisplatin Intraperitoneal Chemotherapy in Patients with Gastric Cancer and Malignant Ascites

Objective: To investigate the value of combined application of compound Kushen injection and cisplatin intraperitoneal chemotherapy in patients with gastric cancer and malignant ascites. Method: The 96 patients with gastric cancer and malignant ascites in our hospital from January 2012 to December 2013 were selected and divided into study group and control group with random number table method, 48 cases in each group. Patients with gastric cancer and malignant ascites in study group were treated with compound Kushen injection combined with cisplatin intraperitoneal chemotherapy, while patients with gastric cancer and malignant ascites in control group were treated with cisplatin intraperitoneal chemotherapy only. The clinical treatment conditions of patients in two groups were compared and analyzed. Result: As compared with the control group, the ratio of partial remission and total effective rate were increased in the patients with gastric cancer in study group, with significant differences (P < 0.05), the improvement ratio of life quality was increased in the study group, with statistically significant differences (P < 0.05), the ratio of reduction was increased, with highly statistically significant difference (P < 0.01), NK cells and CD3⁺ cell were increased significantly, with statistically significant differences (P < 0.05), CD4⁺ cell and CD4⁺/CD8⁺ were increased significantly, while CD8⁺ cell was reduced significantly, with highly statistically significant differences(P < 0.01), the overall incidence of adverse reactions was significantly lower than that in control group, with highly statistically significant difference (P < 0.01). Conclusion: Compound Kushen injection combined with cisplatin intraperitoneal chemotherapy had extremely important practical significance in improving the clinical efficacy, improving quality of life, enhancing immunity, and reducing the adverse reactions for patients with gastric cancer and malignant ascites.